BRIEF-Resverlogix updates On Apabetalone (RVX-208) study
Aug 11 (Reuters) - Resverlogix Corp
* Resverlogix announces positive recommendation from data safety monitoring board for phase 3 study of Apabetalone (RVX-208)
* Data review by independent data safety monitoring board resulted in verbal recommendation for trial to continue as planned Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.